Pharma Nord Lithuania - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 460,783 | 434,373 | 381,073 | 431,209 | 266,104 | 352,698 | 550,179 | 647,018 |
| Profit before tax | 23,040 | 21,660 | 19,239 | 21,406 | 13,305 | 28,184 | 25,920 | 34,831 |
| Net profit | 14,595 | 13,583 | 9,615 | 6,208 | 13,109 | 22,308 | 22,751 | 28,675 |
| Equity | 34,987 | 34,570 | 34,185 | 15,393 | 17,502 | 39,810 | 26,561 | 32,236 |
| Liabilities | 99,466 | 95,874 | 91,112 | 102,257 | 73,022 | 91,754 | 536,177 | 237,641 |
| Non-current assets | 3,591 | 418 | 59 | 0 | 0 | 8,081 | 6,716 | 5,351 |
| Current assets | 126,665 | 130,026 | 125,151 | 117,650 | 90,524 | 122,858 | 510,767 | 258,165 |
| Total assets | 130,256 | 130,444 | 125,210 | 117,650 | 90,524 | 130,939 | 517,483 | 263,516 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 294 | 4,083 | 65,797 |
| Social insurance contributions | - | - | - | - | - | 23,622 | 23,477 | 17,586 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +42.6% | -5.7% | -12.3% | +13.2% | -38.3% | +32.5% | +56.0% | +17.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 11.2% | 10.4% | 7.7% | 5.3% | 14.5% | 17.0% | 4.4% | 10.9% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 41.7% | 39.3% | 28.1% | 40.3% | 74.9% | 56.0% | 85.7% | 89.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 3.2% | 3.1% | 2.5% | 1.4% | 4.9% | 6.3% | 4.1% | 4.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 5.0% | 5.0% | 5.0% | 5.0% | 5.0% | 8.0% | 4.7% | 5.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 2.8 | 2.8 | 2.7 | 6.6 | 4.2 | 2.3 | 20.2 | 7.4 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 51,198 | 49,643 | 47,634 | 51,233 | 46,279 | 81,392 | 110,036 | 146,494 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Pharma Nord Lithuania - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2022-11-21 | 2022-11-27 | 875.55 |
| 2022-11-17 | 2022-11-18 | 875.55 |
| 2021-09-16 | 2021-09-27 | 85.52 |
Pharma Nord Lithuania - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-08-02 | 2026-08-13 | 1005.78 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Pharma Nord Lithuania, UAB (code 304096442) is a Private Limited Liability Company engaged in market research and public opinion polling. In 2025, revenue increased to €647.0K, up 17.6% year on year and 83.5% over two years. Net profit rose to €28.7K, compared with €22.8K in 2024 and €22.3K in 2023, while the profit margin was 4.4% in 2025, after 4.1% in 2024 and 6.3% in 2023. The 2025 balance sheet showed total assets of €263.5K, equity of €32.2K and liabilities of €237.6K, reflecting a leveraged capital structure with an equity ratio of 12.2% and debt-to-equity of 7.37. Asset turnover stood at 2.46x and ROA at 10.9%, while returns on equity were elevated because of the relatively small equity base. Revenue per employee was €161.8K and profit per employee €7.2K.